IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q2 2022
Institutional positions in IO Biotech, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −1 vs. Q1 2022
- Shares held
- 15.5M
- +594.7K (+4.0%) vs. Q1 2022
- Total value
- $72.2M
- −$4.70M (−6.1%) vs. Q1 2022
- New holders
- 5
- 3 more added
- Sold out
- 6
- 3 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,277,932 | $15.3M | 0.75% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,015,545 | $14.1M | 1.41% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 2,159,155 | $10.1M | 0.39% | +797,011+58.5% | Added |
| Avoro Capital Advisors LLC | 2,055,883 | $9.60M | 0.19% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 1,857,755 | $8.68M | 0.23% | 00.0% | Unchanged |
| Capital World Investors | 1,235,000 | $5.77M | 0.00% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,008,437 | $4.71M | 1.26% | −112,000−10.0% | Reduced |
| Soleus Capital Management, L.P. | 655,404 | $3.06M | 0.49% | −17,330−2.6% | Reduced |
| Bridgeway Capital Management, LLC | 75,000 | $350.0K | 0.01% | +75,000 | New |
| Millennium Management LLC | 46,231 | $216.0K | 0.00% | −26,497−36.4% | Reduced |
| Morgan Stanley | 24,109 | $113.0K | 0.00% | +7,622+46.2% | Added |
| Citadel Advisors LLC | 14,426 | $67.0K | 0.00% | +14,426 | New |
| Geode Capital Management, LLC | 12,730 | $59.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 10,000 | $47.0K | 0.00% | 00.0% | Unchanged |
| Cannell Capital LLC | 2,192 | $10.0K | 0.00% | +2,192 | New |
| UBS Group AG | 2,234 | $10.0K | 0.00% | +2,234 | New |
| Citigroup Inc | 1,000 | $5.00K | 0.00% | +836+509.8% | Added |
| Tower Research Capital LLC (TRC) | 524 | $2.00K | 0.00% | +524 | New |
| Vanguard Group Inc | 0 | $0 | 0.00% | −62,234−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −26,676−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −14,280−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −11,126−100.0% | Sold out |
| Stifel Financial Corp | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |